Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Transaction and financial scope

Scinai's wholly owned subsidiary entered into a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company that the company states includes approximately $5.1 million in committed base service fees, subject to performance and the agreement's terms. Scinai says these committed services are expected to contribute to revenue during 2026 and 2027 as performance obligations are satisfied, and that advance and milestone payments are expected to support cash flow and working capital during project execution. The company reported that following execution, Committed Customer Orders across its Jerusalem and Yavne operations reached approximately $7.6 million, up approximately 300% from $1.9 million at year-end 2025.

Sources: S1

Scope of work and timeline

Scinai describes the engagement as covering integrated chemistry, manufacturing and controls development and clinical manufacturing for an investigational oncology product, including process and analytical development, manufacturing readiness, IND-enabling activities, a clinical manufacturing program, stability testing and development of a prefilled-syringe presentation. The company indicates the clinical manufacturing program is planned to begin in January 2027 and that stability services will continue beyond 2027.

Sources: S1

Potential additional and excluded activities

The release states potential additional clinical manufacturing has a combined indicative, uncommitted service-fee value of $5.85 million for late 2027 through the first half of 2028, but notes these activities remain subject to final scope and pricing, written authorization, available capacity and the customer's development and regulatory progress. Scinai also says the indicative value excludes scale-up, manufacturing-suite transition and qualification, the first clinical batch in the new configuration, and project-related costs, and that these potential activities are not included in the initial $5.1 million commitment or in Committed Customer Orders.

Sources: S1

Revenue recognition and additional charges

Scinai states it will bill approved project-related costs separately, including a procurement and handling charge where applicable, and that such charges are expected to generate additional revenue although the amount recognized as revenue may differ from total customer billings under applicable accounting requirements. The company also characterizes Committed Customer Orders as a non-GAAP supplemental operating measure and cautions it does not represent recognized revenue or remaining unfulfilled backlog.

Sources: S1

What remains uncertain

• The $5.1 million service commitment is stated to remain subject to performance and the agreement's terms, including termination rights, and the potential additional $5.85 million is described as indicative and uncommitted; no assurance is given that these activities or commercial manufacturing will proceed.
• Committed Customer Orders is a non-GAAP supplemental measure the company uses to monitor activity and it does not represent recognized revenue or remaining unfulfilled backlog.
• Timelines and revenue recognition depend on service performance, contractual milestones and applicable accounting requirements; projects may be delayed, modified or terminated per the company's disclosure.